-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WD+FlVSHUd59guXgtwN3ZMEudy9QNd+wvmo2hIetZIiwZ+2bbkCnhmZ2JAcaSI69 qsVthjor+28Z9hAYT+Ng+A== 0001104659-05-045823.txt : 20050927 0001104659-05-045823.hdr.sgml : 20050927 20050927071904 ACCESSION NUMBER: 0001104659-05-045823 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050927 FILED AS OF DATE: 20050927 DATE AS OF CHANGE: 20050927 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 BUSINESS ADDRESS: STREET 1: 341 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 341 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ADELMAN DANIEL C MD CENTRAL INDEX KEY: 0001222037 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 051104025 BUSINESS ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 EAST ARQAUES AVENUE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 23 WOODLEAF AVENUE CITY: REDWOOD CITY STATE: CA ZIP: 94061 3 1 a3.xml 3 X0202 3 2005-09-27 0 0001061027 SUNESIS PHARMACEUTICALS INC SNSS 0001222037 ADELMAN DANIEL C MD C/O SUNESIS PHARMACEUTICALS, INC. 341 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Senior VP,Drug Discovery & Dev Incentive Stock Option (right to buy) 0.60 2013-06-10 Common Stock 166666 D Non-Qualified Stock Option (right to buy) 0.60 2013-06-10 Common Stock 33334 D Incentive Stock Option (right to buy) 0.60 2014-01-20 Common Stock 50000 D Incentive Stock Option (right to buy) 0.60 2014-06-23 Common Stock 80000 D 100% of the shares subject to the option are immediately exercisable. However, all unvested shares of common stock underlying the option are subject to a right of repurchase held by the Issuer, which right of repurchase will lapse as the shares vest according to the following schedule: 25% of the shares subject to the option will vest on May 27, 2004 and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on May 27, 2007. 100% of the shares subject to the option are immediately exercisable. However, all unvested shares of common stock underlying the option are subject to a right of repurchase held by the Issuer, which right of repurchase will lapse as the shares vest according to the following schedule: 25% of the shares subject to the option will vest on January 1, 2005 and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on January 1, 2008. 100% of the shares subject to the option are immediately exercisable. However, all unvested shares of common stock underlying the option are subject to a right of repurchase held by the Issuer, which right of repurchase will lapse as the shares vest according to the following schedule: 25% of the shares subject to the option will vest on June 24, 2005 and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on June 24, 2008. /s/ Daryl B. Winter as attorney-in-fact for Dan Adelman 2005-09-27 EX-24 2 ex-24.htm EX-24

Exhibit 24

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes Daryl B. Winter, Ph.D., Eric H. Bjerkholt or Vickie Chou of Sunesis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or stockholder of the Company, Forms 3, 4 and 5, and any Amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned’s beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney’s-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14^th day of September, 2005.

	/s/ Daniel C. Adelman
	Daniel C. Adelman

-----END PRIVACY-ENHANCED MESSAGE-----